Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel

Paclitaxel (PTX) is one of the front-line drugs approved for the treatment of ovarian cancer. However, the application of PTX is limited due to the significant hydrophobicity and poor pharmacokinetics. We previously reported target-directed liposomes carrying tumor-selective conjugated antibody and...

Descripción completa

Detalles Bibliográficos
Autores principales: Khayrani, Apriliana Cahya, Mahmud, Hafizah, Oo, Aung Ko Ko, Zahra, Maram H., Oze, Miharu, Du, Juan, Alam, Md Jahangir, Afify, Said M., Quora, Hagar A. Abu, Shigehiro, Tsukasa, Calle, Anna Sanchez, Okada, Nobuhiro, Seno, Akimasa, Fujita, Koki, Hamada, Hiroki, Seno, Yuhki, Mandai, Tadakatsu, Seno, Masaharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429518/
https://www.ncbi.nlm.nih.gov/pubmed/30818864
http://dx.doi.org/10.3390/ijms20051042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429518/
https://www.ncbi.nlm.nih.gov/pubmed/30818864
http://dx.doi.org/10.3390/ijms20051042

Ejemplares similares